These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 18219838

  • 1. Tolerability of indacaterol, a novel once-daily beta2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study.
    Yang WH, Martinot JB, Pohunek P, Beier J, Magula D, Cameron R, Owen R, Higgins M.
    Ann Allergy Asthma Immunol; 2007 Dec; 99(6):555-61. PubMed ID: 18219838
    [Abstract] [Full Text] [Related]

  • 2. Bronchodilator efficacy of indacaterol, a novel once-daily beta2-agonist, in patients with persistent asthma.
    Pearlman DS, Greos L, LaForce C, Orevillo CJ, Owen R, Higgins M.
    Ann Allergy Asthma Immunol; 2008 Jul; 101(1):90-5. PubMed ID: 18681090
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of indacaterol, a new 24-hour beta2-agonist, in patients with asthma: a dose-ranging study.
    Kanniess F, Boulet LP, Pierzchala W, Cameron R, Owen R, Higgins M.
    J Asthma; 2008 Dec; 45(10):887-92. PubMed ID: 19085578
    [Abstract] [Full Text] [Related]

  • 4. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J, Chanez P, Martinot JB, Schreurs AJ, Tkácová R, Bao W, Jack D, Higgins M.
    Pulm Pharmacol Ther; 2007 Dec; 20(6):740-9. PubMed ID: 17088091
    [Abstract] [Full Text] [Related]

  • 5. Indacaterol provides sustained 24 h bronchodilation on once-daily dosing in asthma: a 7-day dose-ranging study.
    LaForce C, Alexander M, Deckelmann R, Fabbri LM, Aisanov Z, Cameron R, Owen R, Higgins M.
    Allergy; 2008 Jan; 63(1):103-11. PubMed ID: 18053019
    [Abstract] [Full Text] [Related]

  • 6. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study.
    Chuchalin AG, Tsoi AN, Richter K, Krug N, Dahl R, Luursema PB, Cameron R, Bao W, Higgins M, Woessner R, van As A.
    Respir Med; 2007 Oct; 101(10):2065-75. PubMed ID: 17643277
    [Abstract] [Full Text] [Related]

  • 7. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S, Bantje T, Centanni S, Chanez P, Chuchalin A, D'Urzo A, Kornmann O, Perry S, Jack D, Owen R, Higgins M.
    Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM, Gotfried MH, Lawrence D, Lassen C, Kramer B.
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of single therapeutic and supratherapeutic doses of indacaterol versus salmeterol and salbutamol in patients with asthma.
    Brookman LJ, Knowles LJ, Barbier M, Elharrar B, Fuhr R, Pascoe S.
    Curr Med Res Opin; 2007 Dec; 23(12):3113-22. PubMed ID: 17999782
    [Abstract] [Full Text] [Related]

  • 10. Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma.
    Beeh KM, Derom E, Kanniess F, Cameron R, Higgins M, van As A.
    Eur Respir J; 2007 May; 29(5):871-8. PubMed ID: 17251236
    [Abstract] [Full Text] [Related]

  • 11. Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.
    Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T.
    COPD; 2010 Dec; 7(6):418-27. PubMed ID: 21166630
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
    Kinoshita M, Lee SH, Hang LW, Ichinose M, Hosoe M, Okino N, Prasad N, Kramer B, Fukuchi Y, Indacaterol Asian COPD Study Investigators.
    Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
    [Abstract] [Full Text] [Related]

  • 13. Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent asthma: a 52-week, open-label, stratified, parallel-group, multicenter study.
    Cowie RL, Boulet LP, Keith PK, Scott-Wilson CA, House KW, Dorinsky PM.
    Clin Ther; 2007 Jul; 29(7):1390-402. PubMed ID: 17825690
    [Abstract] [Full Text] [Related]

  • 14. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
    Donohue JF, Fogarty C, Lötvall J, Mahler DA, Worth H, Yorgancioglu A, Iqbal A, Swales J, Owen R, Higgins M, Kramer B, INHANCE Study Investigators.
    Am J Respir Crit Care Med; 2010 Jul 15; 182(2):155-62. PubMed ID: 20463178
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R, Chung KF, Buhl R, Magnussen H, Nonikov V, Jack D, Bleasdale P, Owen R, Higgins M, Kramer B, INVOLVE (INdacaterol: Value in COPD: Longer Term Validation of Efficacy and Safety) Study Investigators.
    Thorax; 2010 Jun 15; 65(6):473-9. PubMed ID: 20522841
    [Abstract] [Full Text] [Related]

  • 16. 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma: comparison with placebo and formoterol.
    LaForce C, Korenblat P, Osborne P, Dong F, Higgins M.
    Curr Med Res Opin; 2009 Oct 15; 25(10):2353-9. PubMed ID: 19650753
    [Abstract] [Full Text] [Related]

  • 17. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
    Beeh KM, Wagner F, Khindri S, Drollmann AF.
    COPD; 2011 Oct 15; 8(5):340-5. PubMed ID: 21793716
    [Abstract] [Full Text] [Related]

  • 18. Once-daily evening administration of mometasone furoate in asthma treatment initiation.
    Bensch GW, Prenner B, Berkowitz R, Galant S, Ramsdell J, Lutsky B.
    Ann Allergy Asthma Immunol; 2006 Apr 15; 96(4):533-40. PubMed ID: 16680923
    [Abstract] [Full Text] [Related]

  • 19. Once-daily budesonide inhalation powder (Pulmicort Turbuhaler) maintains pulmonary function and symptoms of asthmatic children previously receiving inhaled corticosteroids.
    Shapiro GG, Mendelson LM, Pearlman DS.
    Ann Allergy Asthma Immunol; 2001 Jun 15; 86(6):633-40. PubMed ID: 11428735
    [Abstract] [Full Text] [Related]

  • 20. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC, Fiske K, Lyne A.
    Clin Ther; 2007 Sep 15; 29(9):1967-79. PubMed ID: 18035196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.